The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells

The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells

In the clinical practice, the combination of 5-fluorouracil (5-FU) + Adriamycin (also known as doxorubicin, DOX) + cyclophosphamide (CYA) (known as FAC) is used to treat breast cancer. The FAC therapy, however, carries some serious risks, namely potential cardiotoxic effects, although the mechanisms...

Full description

Bibliographic Details
Main Authors: Ana Reis-Mendes, Félix Carvalho, Fernando Remião, Emília Sousa, Maria de Lourdes Bastos, Vera Marisa Costa
Format: Article
Language:English
Published: MDPI AG 2019-03-01
Series:Biomolecules
Subjects:
doxorubicinol
fluoro-β-alanine
acrolein
cardiotoxicity
differentiated H9c2 cells
Online Access:http://www.mdpi.com/2218-273X/9/3/98

Similar Items

Similar Items